I did exactly this. Was on Wegovy 2.4mg, insurance dropped it, switched to compounded sema at the same dose. Honestly the transition was seamless for me — same drug, same dose, just different source. The main difference is going from an auto-injector pen to drawing from a vial with an insulin syringe, which takes some getting used to but YouTube tutorials help.

Cost went from $1,349/month with no insurance coverage to $165/month from a compounding pharmacy. Same drug. Let that pricing disparity sink in.

Make sure your telehealth provider writes the script for the same dose you were on. Some try to restart you at a low dose "to be safe" which is unnecessary if you've been on the drug for over a year.

OP again. Thank you all. This is making me feel less alone in this. I think I'm going to look into compounded as a bridge option. The idea of going through what you described at weeks 2-6 while also dealing with work stress and life is genuinely scary.

The insurance thing makes me so angry. 16 months of documented success — A1C went from 6.8 to 5.4, lost 74lbs, off blood pressure meds — and they're pulling coverage because some actuary decided GLP-1s cost too much. So they'd rather pay for the heart attack in 10 years? Make it make sense.

I want to add that if you can afford even a PARTIAL dose while transitioning, it helps enormously. When the shortage hit I couldn't get my 1mg dose but I could get 0.25mg. Even that tiny maintenance dose kept the worst of the rebound at bay. Better than cold turkey by a mile.

This is a good point. There's a concept in pharmacology called "receptor occupancy" — even a low dose that maintains partial GLP-1 receptor activation can blunt the rebound response. Going from 2mg to 0.25mg is a huge step-down, but it's pharmacologically distinct from going to zero. If cost is the limiting factor, a lower dose of compounded sema is very affordable and could serve as a step-down bridge.

Also — discuss metformin with your doctor as a maintenance strategy. It's generic, dirt cheap ($4-10/month), and while it works through different mechanisms than GLP-1 RAs, it provides some appetite reduction and glucose control that may help mitigate regain. Several endocrinologists are now using metformin as a "bridge" medication post-GLP-1 discontinuation.